Mena FN

Isomab Makes Two Key Appointments Dr Shi Yin Foo M.D. As Non-Executive Director And Dr Gary Burgess M.D. As Chief Medical Officer

Aim to accelerate progress of lead candidate ISM-001 for peripheral ischaemia to clinic NOTTINGHAM, England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd , a UK-based biotechnology company developing ...
KRON4 News

IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer

NOTTINGHAM, England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease ...